top of page

ASGCT 2026: Siren Biotechnology recently has seen two INDs cleared for its AAV based gene therapy for oncology. Founder Nicole Paulk discusses how they are prepared to enter the clinic shortly

  • May 13
  • 1 min read

She describes how the first trials will target glioma, a type of brain cancer, and Siren has also done work to show that the approach could be a universal therapy that may have utility against numerous cancers. Plus, how Siren did a unique crowdfunded $5 million fundraise.




Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page